Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

46.85 +2.51 (+5.66%)

Streaming Delayed Price Updated: 2:05 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

20 Stocks Moving in Wednesday's Pre-Market Session ↗

October 13, 2021

Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-...

Via Benzinga

Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall? ↗

October 12, 2021

Crispr is planning to begin a registrational test in the first quarter of 2022.

Via Investor's Business Daily

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...

Via Benzinga

Analyzing CRISPR Therapeutics's Unusual Options Activity ↗

August 11, 2021

Shares of CRISPR Therapeutics (NASDAQ:CRSP) saw some unus...

Via Benzinga

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

Why CRISPR Therapeutics Stock Fell 10.4% Last Month ↗

October 07, 2021

CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.

Via The Motley Fool

These 3 Top Healthcare Stocks Are Screaming Buys Right Now ↗

September 29, 2021

If the market crashes these companies could be insulated.

Via The Motley Fool

Biotech Playbook Revisited As Technicals Weaken ↗

September 27, 2021

Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...

Via Talk Markets

3 Explosive Biotech Stocks That Could 10X in 10 Years ↗

September 16, 2021

They're leaders in therapeutic areas with massive growth potential.

Via The Motley Fool

Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market ↗

September 09, 2021

Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.

Via Talk Markets

Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought ↗

September 09, 2021

All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.

Via The Motley Fool

Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics ↗

September 04, 2021

Vertex plans to work more closely on CRISPR gene editing with a small privately-held biotech.

Via The Motley Fool

Could CRISPR Therapeutics Stock Help You Retire a Millionaire? ↗

August 31, 2021

A crowded field could take years to thin out.

Via The Motley Fool

Vaccine Victory ↗

August 24, 2021

Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson...

Via Talk Markets

Topics Economy

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today ↗

August 23, 2021

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.

Via InvestorPlace

Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics ↗

August 19, 2021

Currently trading at a very reasonable multiple, CRSP stock is an undeniable buy.

Via InvestorPlace

Why CRISPR Therapeutics Stock Fell 25.2% in July ↗

August 06, 2021

The stock dropped roughly $40 per share over the course of the month.

Via The Motley Fool

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today ↗

August 05, 2021

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.

Via InvestorPlace

Better Buy: Vertex vs. CRISPR ↗

July 31, 2021

Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.

Via The Motley Fool

CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today ↗

July 30, 2021

Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate.

Via InvestorPlace

Why CRISPR Therapeutics' Stock Is Trading Higher Today ↗

July 30, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading higher Friday morning after the company announced second-quarter financial results that showed significant improvement year over...

Via Benzinga

Why CRISPR Therapeutics' Stock Is Trading Higher Today ↗

July 29, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year. 'We expect...

Via Benzinga

Crispr Therapeutics Represents the Best of Emerging Biotechnology ↗

July 26, 2021

CRSP stock may end up being a pioneer, or it may fizzle. The timeline until we know is typical of biotech stocks.

Via InvestorPlace

Is CRISPR Therapeutics a Millionaire-Maker Stock? ↗

July 24, 2021

It's already well on its way, but the road ahead will be long.

Via The Motley Fool

Topics Initial Public Offering

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

July 23, 2021

The company is on track to be the first to market with a gene-editing therapy for blood disorders.

Via The Motley Fool

Crispr Therapeutics Has Bullish DNA ↗

July 22, 2021

Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning.

Via InvestorPlace

Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns? ↗

July 19, 2021

Ethical concerns will likely dog CRISPR Therapeutics stock, especially with the present social awakening.

Via InvestorPlace

Topics Economy

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗

July 16, 2021

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Via The Motley Fool

Cramer Gives His Opinion On Wynn Resorts, Advanced Micro Devices And More ↗

July 14, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Blackstone Group Inc (NYSE: BX) very much. He keeps buying Wynn Resorts, Limited (NASDAQ: WYNN) for...

Via Benzinga

How Investors Can Own A Piece Of Tesla, Shopify, CRISPR Therapeutics ↗

July 12, 2021

Investing in the ARK Innovation ETF (NYSE:ARKK) is the ...

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.